WCM
TXMD icon

Weld Capital Management’s TherapeuticsMD TXMD Stock Holding History

Weld Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-960
Closed -$183K – 887
2018
Q4 		$183K Buy
+960
New +$234K 0.04% 597

Other funds holding TXMD

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Weld Capital Management's TXMD Position: Q1 2019 in Review

Weld Capital Management sold out of TherapeuticsMD (TXMD) in Q1 2019, closing a stake of 960 shares — an estimated $183K sold.

Weld Capital Management first reported a position in TXMD in Q4 2018 and held it in 1 quarter. The position peaked at $183K in Q4 2018. 146 funds tracked by Wall St. Rank hold TXMD as of Q1 2019.

  • Weld Capital Management reported no remaining TherapeuticsMD position as of Q1 2019 after selling out during the quarter.
  • Weld Capital Management sold 960 TherapeuticsMD shares in Q1 2019, an estimated $183K.
  • Weld Capital Management first reported a position in TherapeuticsMD in Q4 2018 and held it in 1 quarter.
  • Weld Capital Management's TherapeuticsMD position peaked at $183K in Q4 2018.
  • 146 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2019.

Based on Weld Capital Management's 13F filing for Q1 2019, filed 15 May 2019.